Process for the Preparation of Oxazolidinone Derivatives
AssigneeDIPHARMA FRANCIS S.r.I.
InventorsLino Colombo, Pietro Allegrini, Marco Brusasca, Giuseppe D'Arienzo, Gabriele Razzetti
Life of this patent
Estimating the term…
Abstract
A process for the preparation of oxazolidinone derivatives, in particular [(S)—N-[[3-(3-fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide] (linezolid), and novel intermediates useful for the synthesis thereof.
Claims18
A process for the preparation of a compound of formula (I), or a salt thereof, both as the single (S) or (R) enantiomer, and as a mixture thereof,
- wherein R and R1, which can be the same or different, are hydrogen, CH3, CN, COOH or COOC1-C4 alkyl;
- R2 and R3, which can be the same or different, are hydrogen, F or Cl;
- and
- R4 is C1-C4 alkyl;
- which process comprises:
- a) the activation of the hydroxyl group in a compound of formula (II), or a salt thereof, as the single (S) or (R) enantiomer or as a mixture thereof, by means of a derivatization reagent to form a leaving group, and subsequent cyclization reaction in the presence of a catalyst or an azide compound;
- or
- b) the cyclization reaction of a compound of formula (II), or a salt thereof, as the single (S) or (R) enantiomer or as a mixture thereof, in presence of a strong base;
- wherein R5 is optionally substituted C1-C4 alkyl, aryl-C1-C4 alkyl or aryl;
- and R-R4 are as defined above;
- and,
- if desired, the resolution of a mixture of enantiomers of formula (I) to the single (S) or (R) enantiomer;
- and/or, if desired, the conversion of a compound of formula (I) to a salt thereof, or vice versa.
A compound of formula (II),
- or a salt thereof, both as the single (S) or (R) enantiomer, and as a mixture thereof, wherein R and R1, which can be the same or different, are hydrogen, CH3, CN, COOH or COOC1-C4 alkyl;
- R2 and R3, which can be the same or different, are hydrogen, F or Cl;
- R4 is C1-C4 alkyl and R5 is benzyl, t-butyl, isopropyl, isobutyl, methyl or ethyl.
[(S)—N-[[3-(3-Fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide] with a purity equal to or higher than 95%.
[(S)—N-[[3-(3-Fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide], or a salt thereof, with a mean particles size D50 ranging from about 10 to 250 micrometres.
Dependencies are inferred from the claim text.